GlassScriptPhysician profile
Heidi R Beavan
NPI 1316311624
$6,861.11
in general payments reported to CMS, 2019-2025
27 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $717 · 2022: $1,191 · 2023: $1,350 · 2024: $2,345 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,833 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,833.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,565.74 | 2021-2025 | |
| Genzyme Corporation | $493.97 | 2021-2024 | |
| Evoke Pharma, INC. | $476.11 | 2022-2024 | Gimoti |
| Gilead Sciences, INC. | $451.89 | 2022-2024 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $436.63 | 2021-2024 | Airsupra |
| Idorsia Pharmaceuticals US INC | $425.26 | 2023-2024 | Tryvio, Quviviq |
| Sumitomo Pharma America, INC. | $329.32 | 2024-2025 | Gemtesa, Myfembree |
| Sanofi-Aventis U.S. LLC | $245.38 | 2024 | |
| Novo Nordisk INC | $245.13 | 2022-2025 | Wegovy |
| Ultragenyx Pharmaceutical INC. | $225.04 | 2022-2023 | Crysvita |
| Astellas Pharma US INC | $216.22 | 2024 | Cresemba, Veozah |
| Kyowa Kirin, INC. | $214.78 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $153.67 | 2023 | |
| Phathom Pharmaceuticals, INC. | $123.68 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.11 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $121.85 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $120.68 | 2023 | Yupelri |
| Insulet Corporation | $116.62 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $108.29 | 2022 | |
| Corcept Therapeutics | $107.39 | 2024 | Korlym |
| Paratek Pharmaceuticals, INC. | $100.49 | 2022 | |
| Mayne Pharma Commercial LLC | $95.69 | 2024 | |
| Biogen, INC. | $95.46 | 2025 | Zurzuvae |
| Neurelis, INC. | $93.00 | 2025 | Valtoco |
| Acadia Pharmaceuticals INC | $78.30 | 2024 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $49.95 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $48.46 | 2022-2024 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Beavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.